Market open

Theravance Biopharma/$TBPH

14:30
22:10
05:45
13:25
21:00
1D1W1MYTD1Y5YMAX

About Theravance Biopharma

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Ticker

$TBPH
Sector
Health Care
Trading on
NASDAQ

Industry

Pharmaceuticals
Headquarters
South San Francisco, United States

Employees

99
Website
www.theravance.com

TBPH Metrics

BasicAdvanced
$419M
-
-$1.01
0.22
-

$419M

0.22

$10.44

$7.44

178K

4.97

4.617

21.968

21.968

-15.63%

-6.41%

-22.88%

6.595

2.26

2.26

-33.865

15.93%

6.00%

2.26%

-33.09%

What the Analysts think about TBPH

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.

TBPH Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TBPH Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

TBPH News

AllArticlesVideos
Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript

Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript

Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TBPH

$

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Theravance Biopharma stock?

Theravance Biopharma (TBPH) has a market cap of $419M as of January 15, 2025.

What is the P/E ratio for Theravance Biopharma stock?

The price to earnings (P/E) ratio for Theravance Biopharma (TBPH) stock is 0 as of January 15, 2025.

Does Theravance Biopharma stock pay dividends?

No, Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Theravance Biopharma dividend payment date?

Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders.

What is the beta indicator for Theravance Biopharma?

Theravance Biopharma (TBPH) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.